Pay in 4 interest-free payments of $6.67 Learn more
Ships within 48 hours · Estimated delivery Nov 5 - Nov 10
However, no FDA-approved generics exist yet (as of 2025), due to patent protections
Neuropharmacology 117 , 273281 (2017)
The new Most-Favored-Nation model finally forces price parity while keeping innovation alivean approach that could expand access, improve public health, and make U.S
Head-to-head comparative trials and studies of combination regimens are needed to establish optimal treatment sequencing and identify which patients benefit most from each approach or from their combination
While short-term studies show reasonable safety, long-term effects on skin cancer risk are not definitively known
US$ 27.22
US$ 29.02
US$ 28.02
US$ 21.91
US$ 22.68
US$ 23.64
US$ 23.58
US$ 27.35
US$ 22.11
